Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

Show simple item record

dc.contributor.author Kolstad, Arne
dc.contributor.author Pedersen, Lone Bredo
dc.contributor.author Eskelund, Christian W.
dc.contributor.author Husby, Simon
dc.contributor.author Gronbaek, Kirsten
dc.contributor.author Jerkeman, Mats
dc.contributor.author Laurell, Anna
dc.contributor.author Räty, Riikka
dc.contributor.author Elonen, Erkki
dc.contributor.author Andersen, Niels Smedegaard
dc.contributor.author Brown, Peter deNully
dc.contributor.author Kimby, Eva
dc.contributor.author Bentzen, Hans
dc.contributor.author Sundstrom, Christer
dc.contributor.author Ehinger, Mats
dc.contributor.author Karjalainen-Lindsberg, Marja-Liisa
dc.contributor.author Delabie, Jan
dc.contributor.author Ralfkiaer, Elisabeth
dc.contributor.author Fagerli, Unn-Merete
dc.contributor.author Nilsson-Ehle, Herman
dc.contributor.author Lauritzsen, Grete Fossum
dc.contributor.author Kuittinen, Outi
dc.contributor.author Niemann, Carsten
dc.contributor.author Geisler, Christian Hartman
dc.contributor.author Nordic Lymphoma Grp
dc.date.accessioned 2018-05-06T21:12:28Z
dc.date.available 2021-12-17T18:47:30Z
dc.date.issued 2017-03
dc.identifier.citation Kolstad , A , Pedersen , L B , Eskelund , C W , Husby , S , Gronbaek , K , Jerkeman , M , Laurell , A , Räty , R , Elonen , E , Andersen , N S , Brown , P D , Kimby , E , Bentzen , H , Sundstrom , C , Ehinger , M , Karjalainen-Lindsberg , M-L , Delabie , J , Ralfkiaer , E , Fagerli , U-M , Nilsson-Ehle , H , Lauritzsen , G F , Kuittinen , O , Niemann , C , Geisler , C H & Nordic Lymphoma Grp 2017 , ' Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years ' , Biology of Blood and Marrow Transplantation , vol. 23 , no. 3 , pp. 428-435 . https://doi.org/10.1016/j.bbmt.2016.12.634
dc.identifier.other PURE: 83800472
dc.identifier.other PURE UUID: 5fc860cf-33ed-40a5-92c4-3abe13f0dcb8
dc.identifier.other WOS: 000395367300009
dc.identifier.other Scopus: 85009455648
dc.identifier.uri http://hdl.handle.net/10138/234697
dc.description.abstract The main objectives of the present study were to monitor minimal residual disease (MRD) in the bone marrow of patients with mantle cell lymphoma (MCL) to predict clinical relapse and guide preemptive treatment with rituximab. Among the patients enrolled in 2 prospective trials by the Nordic Lymphoma Group, 183 who had completed autologous stem cell transplantation (ASCT) and in whom an MRD marker had been obtained were included in our analysis. Fresh samples of bone marrow were analyzed for MRD by a combined standard nested and quantitative real-time PCR assay for Bcl-1/immunoglobulin heavy chain gene (IgH) and clonal IgH rear-rangements. Significantly shorter progression-free survival (PFS) and overall survival (OS) was demonstrated for patients who were MRD positive pre-ASCT (54 patients) or in the first analysis post-ASCT (23 patients). The median PFS was only 20 months in those who were MRD-positive in the first sample post-ASCT, compared with 142 months in the MRD-negative group (P en
dc.format.extent 8
dc.language.iso eng
dc.relation.ispartof Biology of Blood and Marrow Transplantation
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject Mantle cell lymphoma
dc.subject Autologous stem cell
dc.subject transplantation
dc.subject Minimal residual disease
dc.subject Preemptive rituximab
dc.subject MINIMAL RESIDUAL DISEASE
dc.subject PROGRESSION-FREE SURVIVAL
dc.subject TIME QUANTITATIVE PCR
dc.subject RANDOMIZED-TRIALS
dc.subject MULTIPLE-MYELOMA
dc.subject PROGNOSTIC INDEX
dc.subject IMMUNOCHEMOTHERAPY
dc.subject REMISSION
dc.subject NETWORK
dc.subject PHASE-2
dc.subject 3121 General medicine, internal medicine and other clinical medicine
dc.subject 3122 Cancers
dc.title Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years en
dc.type Article
dc.contributor.organization Hematologian yksikkö
dc.contributor.organization Clinicum
dc.contributor.organization Department of Oncology
dc.contributor.organization Department of Medicine
dc.contributor.organization University of Helsinki
dc.contributor.organization Medicum
dc.contributor.organization Department of Pathology
dc.contributor.organization HUS Comprehensive Cancer Center
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1016/j.bbmt.2016.12.634
dc.relation.issn 1083-8791
dc.rights.accesslevel openAccess
dc.type.version publishedVersion

Files in this item

Total number of downloads: Loading...

Files Size Format View
1_s2.0_S1083879116312125_main.pdf 1.888Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record